Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Section II - Screening, Prevention, and Early Diagnosis
Published online by Cambridge University Press: 20 July 2023
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 11 - 22Publisher: Cambridge University PressPrint publication year: 2023
References
References
National Comprehensive Care Network. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 2. 2021. Available from: www.nccn.orgGoogle Scholar
Rebbeck, TR, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346(21):1616–1622CrossRefGoogle ScholarPubMed
Mai, PL, et al. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: and NRG Oncology/GOG Study. Gynecol Oncol 2020;156(1):131–139.CrossRefGoogle ScholarPubMed
Long, Roche KC, et al. Risk-reducing salpingectomy: let us be opportunistic. Cancer 2017;123(10):1714–1720.CrossRefGoogle Scholar
References
Bowtell, DD, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 2015;15(11):668–679.CrossRefGoogle ScholarPubMed
Kotsopoulos, J, et al. Hereditary Ovarian Cancer Clinical Study Group. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 2020;2020:S0090–8258.Google Scholar
Gronwald, J, et al. A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. Gynecol Oncol 2019;155(2):270–274. https://doi.org/10.1016/j.ygyno.2019.08.034CrossRefGoogle ScholarPubMed
Finch, AP, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32(15):1547–1553.CrossRefGoogle ScholarPubMed
Metcalfe, K, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 2015;1(3):306–313.CrossRefGoogle ScholarPubMed
Evans, DG, et al. Survival from breast cancer in women with a BRCA2 mutation by treatment. Br J Cancer 2021;124(9):1524–1532.CrossRefGoogle ScholarPubMed
Lugo Santiago, N, et al. Ovarian cancer after prophylactic salpingectomy in a patient with germline BRCA1 mutation. Obstet Gynecol 2020;135(6):1270–1274. https://doi.org/10.1097/AOG.0000000000003864CrossRefGoogle Scholar
References
US Preventive Services Task Force, et al. Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;320:674–686.Google Scholar
Gage, JC, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014;56(5):106.Google Scholar
Wright, TC, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015;136:189–197.CrossRefGoogle ScholarPubMed
Food and Drug Administration. FDA Summary of Safety and Effectiveness Data; cobas HPV for use on the cobas 6800/8800 System. 2020.Google Scholar
Food and Drug Administration. FDA Summary of Safety and Effectiveness Data; BD Onclarity HPV Assay. 2018.Google Scholar
References
World Health Organization. Human papillomavirus (HPV) and cervical cancer. Geneva: WHO, 2018. Available at: www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer [last accessed October 18, 2022].Google Scholar
Koliopoulos, G, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017;8(8):CD008587.Google ScholarPubMed
United States Preventive Service Task Force. Cervical Cancer: Screening. 2018. Available at: www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening [last accessed October 18, 2022].Google Scholar
Public Health England with NHS England and NHS Improvement Public Health Commissioning. NHS public health functions agreement 2019–2020 Service specification No.25; Cervical Screening Programme. PHE England, 2020.Google Scholar
Fontham, ETH, et al. Cervical cancer screening for individuals at average risk: 2020 Guideline Update from the American Cancer Society. CA Cancer J Clin 2020;70(5):321–346.Google ScholarPubMed